Dmitri O. Rozhkov

Dmitri O. Rozhkov

Auto-generated profile, based on publicly available information

Dmitri O. Rozhkov

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2024 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
KSK. V. Shevtsova
K. V. Shevtsova
DRD. O. Rozhkov
D. O. Rozhkov
DGD. A. Grishina
D. A. Grishina
VGVladislav Griniuk
Vladislav Griniuk
VZV. V. Zakharov
V. V. Zakharov
VPV. A. Parfenov
V. A. Parfenov
Diagnostic hypothesis of Alzheimer's disease (AD) is based on the typical clinical picture of the disease and the exclusion of other diseases manifesting by cognitive and behavioural disorders by MRI scans of the brain and laboratory tests. For an accurate diagnosis of AD and exclusion of other diseases, detection of biological markers (biomarkers) of AD in the cerebrospinal fluid (CSF) is of great importance: a decrease in the level of beta-amyloid (Ав^ -42) and an increase in the level of phosphorylated tau protein. The analysis of AD biomarkers in the CSF of 63 patients (16 men and 47 women, mean age 72±8.7 years) with a typical picture of AD [30 patients in the moderate cognitive impairment (MCI) stage and 33 in the mild dementia stage] allowed us to confirm the diagnosis in 54 cases (85.3%) and to exclude it in the remaining nine patients (14.7%). We present a case of a 59-year-old patient with MCI in whom biomarkers typical of AD were detected in the CSF, confirming the diagnosis of AD. We also present the observations of two patients with possible AD, in whom the results of the CSF examination made it possible to rule out AD and indicated hippocampal sclerosis and tauopathy. At present, an accurate diagnosis of AD based on the study of biomarkers of the disease is of great practical importance, since at the stage of MCI and mild dementia it is possible to prevent the progression of AD with anti-amyloid therapy. Currently, AD is rarely diagnosed in our country, so it is of great importance to inform physicians about modern methods of diagnosis and treatment of AD.

19 April 2020 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
DRD. O. Rozhkov
D. O. Rozhkov
OZO. E. Zinovyeva
O. E. Zinovyeva
ABA. N. Barinov
A. N. Barinov
IVI. M. Vikhlyantsev
I. M. Vikhlyantsev
GMG. Z. Mikhailova
G. Z. Mikhailova
ANA. M. Nosovsky
A. M. Nosovsky
Objective: to elucidate the frequency and pathogenesis of myofascial pain syndrome (MFPS) in chronic nonspecific lower back pain (CNLBP) and to optimize the diagnosis and treatment of MFPS in CNLBP. Patients and methods. The investigation covered 121 patients with CNLBP. The patients' mean age was 42.1±10.5 years; the pain duration was 7.9±4.3 months. The possible causes of CNLBP were determined: these were facet joints (FJs); sacroiliac joints (SIJs); skeletal muscles with the development of MFPS; MFPS concurrent with FJs; MFPS concurrent with SIJs. Twenty patients had MFPS only (its mean duration was 5.3±2.2 months; the mean pain intensity scores were 6.5±1.1 on a numerical rating scale). Six patients underwent examinations of open biopsy specimens of the muscle straightening the spinal column; a comparison group consisted of 3 healthy women matched for age and gender. The patients were prescribed therapy with aceclofenac 200 mg/day in combination with tolperisone 450 mg/day and nondrug therapy (cognitive behavioral therapy and kinesio- and ergotherapy). When the treatment was insufficiently effective, ultrasonography of the muscle straightening the spinal column was additionally performed; a local anesthetic was injected into myofascial trigger points (MTPs). Results and discussion. MFPS was a cause of pain syndrome in 63 (52%) patients, while MFPS this was an isolated cause of pain in 20 (16.5%) cases and was concurrent with FJ osteoarthritis in 23 (19%), and with SIJ dysfunction in 20 (16.5%). Muscle ultrasonography in patients with MFPS revealed MTPs, whereas examinations of biopsy specimens of the muscle straightening the spinal column showed no evidence of necrosis, fibrosis, or inflammatory infiltration in the presence of transformation of the myosin phenotype, by increasing the proportion of rapidly fatigued type II muscle fibers. The results of sodium dodecyl sulfate (SDS) gel electrophoresis indicated a decrease in the content of titin and nebulin, the sarcomeric cytoskeletal proteins involved in maintaining muscle contractility. A two-week cycle of therapy with aceclofenac and tolperisone reversed pain syndrome in 5 (25%) of the 20 patients and reduced the intensity of back pain in 15 (75%), but the pain increased during physical exercise and impeded active rehabilitation. The additional administration of anesthetics into MTPs and the continuous intake of aceclofenac and tolperisone in combination with kinesiotherapy could relieve pain syndrome and enhance motor activity. Conclusion. More than half of the patients with CNLBP had MFPS only or concurrent with joint pathology (FS and FJs). The changes found in the back muscle biopsy specimens of patients with CNLBP are potentially reversible and can be reversed during kinesiotherapy.

15 January 2025 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Verified
Journal Article
Closed access
MKMarina Kinkulkina
Marina Kinkulkina
ADAlexey B. Danilov
Alexey B. Danilov
Beatrice VolelBeatrice Volel
Beatrice Volel
EMEvgeny Morozov
Evgeny Morozov
DRD. O. Rozhkov
D. O. Rozhkov
VTVadim V. Tarasov
Vadim V. Tarasov
Prevalence of anxiety disorders has increased in last decades, specifically in COVID-19 pandemic. Despite the frequency and burden of post-COVID anxiety disorders, there are still no recommendations for the treatment of these conditions. The article presents the interim results of a post-registration multicenter observational study of the efficacy and safety of a new original drug Aviandr in the treatment of anxiety developing after COVID-19. The study included 170 patients over 18 years of age treated by Aviandr for 6 weeks at a dose of 20 mg 2 times a day. All patients completed 6 weeks of treatment and 2 weeks of follow-up. The decrease in the average total score of the Hamilton Rating Scale for Anxiety (SIGH-A) was 77.13 % of the baseline values. Most patients experienced clinical improvement; 72.35 % patients have reached remission by week 6 of therapy. The drug was equally effective in different age groups (≤/> 65 years). It is important to note that Aviandr was effective in relieving both mental and somatic anxiety, measured with SIGH-A scale — the reduction in average scores was 75.13 % and 79.12 %, respectively. The study drug showed a good safety profile. Adverse events were observed in 5.88 % of patients; 85.7 % of AEs were mild, only 14.3 % were moderate. Thus, Aviandr showed good efficacy in the treatment of anxiety disorders after COVID-19. The absence of withdrawal syndrome, drug dependence, a high safety profile, including in elderly patients, make Aviandr a good choice for use in clinical practice.

1 December 2019 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
DRD. O. Rozhkov
D. O. Rozhkov
OZO. E. Zinov’yEva
O. E. Zinov’yEva
Ivan VikhlyantsevIvan Vikhlyantsev
Ivan Vikhlyantsev
GMG. Z. Mikhaylova
G. Z. Mikhaylova
AUA. D. Ulanova
A. D. Ulanova
ABA. N. Barinov
A. N. Barinov
Back pain in terms of socio-economic losses over the past 5 years has come to the first place among the causes of disability, and therefore the problem of rapid effective anesthesia and rehabilitation of this large group of patients is topical. In most cases, the main sources of back pain are the structures of the musculoskeletal system, and the reasons are their microtraumatization due to sudden unprepared movements, prolonged stay in a static position, heavy physical labor. The task of clinical and instrumental examination is to exclude specific causes of dorsalgia. It is also important to present the results of the survey in an accessible form, in particular to correctly interpret the data from neuroimaging research methods. Adequate anaesthesia for acute back pain, informing the patient about the favorable prognosis of the disease and early motor activation are essential to prevent the transition of the physiological feeling of pain into the pathological process - chronic pain syndrome. When dealing with chronic pain, the interaction of specialists of different profiles in the multidisciplinary team is required. Kinesiotherapy, ergotherapy, cognitive-behavioural therapy are the main methods of non-drug treatment of lower back painIt is recommended that the patient maintains the usual level of physical activity and then increases it. It is necessary to teach the patient to correctly perform movements in the social, professional and domestic spheres, to explain how to avoid unsafe movements that can provoke dorsalgia. The article presents the observation of a patient with chronic back pain. Success in treatment has been achieved through effective anesthesia through rational selection of non-steroidal anti-inflammatory drugs (Dexalgin), local administration of local anesthetics to overcome kinesiophobia, and a combination of cognitive-behavioural therapy, kinesiotherapy, and ergotherapy.

24 October 2022 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
DRD. O. Rozhkov
D. O. Rozhkov
KSK. V. Shevtsova
K. V. Shevtsova
VGVladislav Griniuk
Vladislav Griniuk
VPVladimir Parfenov
Vladimir Parfenov
Objective: non-interventional study ELBRUS (Etoricoxib in the Treatment of Back Pain) was conducted to investigate the efficacy and safety of daily administration of Rixia® (Etoricoxib) 60 mg per day in patients with chronic non-specific low back pain (CNSLBP).Patients and methods. The study included 50 patients (31 women and 19 men, mean age 54.3±16.8 years) with CNSLBP. Educational conversation, cognitive therapy, regular therapeutic exercises, identification and treatment of comorbidities were conducted. Patients received etoricoxib 60 mg once daily. Pain intensity was assessed on a 10-point numerical rating scale (NRS), pain-related disability was assessed on the Oswestry Scale (ODS), and emotional state was assessed on the Hospital Anxiety and Depression Scale (HADS).Results and discussion. The causes of CNSLBP were: in 5 (10%) patients – sacroiliac joint involvement, in 14 (28%) – lower lumbar facet joints involvement, in 3 (6%) – myofascial pain, the remaining 28 (56%) patients had a combination of several reasons. As a result of complex treatment, the intensity of pain at rest decreased on average from 4.0±2.5 to 1.4±1.3 points, while moving – from 6.6±1.9 to 2.8±1.8 points, at night – from 2.7±2 to 0.7±0.9 points according to the NRS, disability – from 39±18.9 to 19.9±14.6% according to the ODS, the severity of anxiety – from 6.5±3.9 to 3.3±2.4 points and depression from 5.0±3.7 to 3.1±2.9 points according to HADS (p˂0.001). The duration of treatment was 14.14±3.6 days on average. No adverse events were observed during treatment with etoricoxib.Conclusion. The efficacy and safety of etoricoxib in the complex therapy of patients with CNSLBP was noted.

8 December 2019 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
DRD. O. Rozhkov
D. O. Rozhkov
OZO. E. Zinovyeva
O. E. Zinovyeva
ABA. N. Barinov
A. N. Barinov
ANA. M. Nosovsky
A. M. Nosovsky
Facet joint osteoarthritis as a cause of chronic low back pain